The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database

Tofacitinib is an oral, small-molecule Janus kinase inhibitor approved in South Korea for the treatment of moderate to severe ulcerative colitis (UC) on May 1, 2019. However, safety data are lacking. We investigated the incidence of serious adverse events (SAEs) in patients with UC using tofacitinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Gi Hyeon, Jung, Sung Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039199/
https://www.ncbi.nlm.nih.gov/pubmed/35470598
http://dx.doi.org/10.3346/jkms.2022.37.e123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039199/
https://www.ncbi.nlm.nih.gov/pubmed/35470598
http://dx.doi.org/10.3346/jkms.2022.37.e123

Ejemplares similares